Subscribe
shutterstock_1635596416_sundry_photography
Sundry Photography / Shutterstock.com
1 April 2021BiotechnologyBenjamin Pelletier

The uncertain future of antibody claims

A long string of decisions from the US Court of Appeals for the Federal Circuit has undermined support for purely functional antibody epitope claims through the written description and enablement requirements of 35 USC §112.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Haynes Boone hires top biotech patent lawyer
19 July 2022   New partner boosts firm’s biotech practice | Move forms part of life sciences expansion | Role based at Washington, DC office.
Big Pharma
Sanofi and C4X in $493m licensing deal
13 April 2021   UK company C4X Discovery has agreed an exclusive licensing deal with Sanofi worth a potential €414 million, which will see the French pharmaceutical company develop anti-inflammatory therapies.
Americas
Amgen antibody patents ‘too broad’, says Fed Circuit
16 February 2021   The US Court of Appeals for the Federal Circuit has invalidated two Amgen antibody patents, finding that their functional claims were too broad.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Americas
Haynes Boone hires top biotech patent lawyer
19 July 2022   New partner boosts firm’s biotech practice | Move forms part of life sciences expansion | Role based at Washington, DC office.
Big Pharma
Sanofi and C4X in $493m licensing deal
13 April 2021   UK company C4X Discovery has agreed an exclusive licensing deal with Sanofi worth a potential €414 million, which will see the French pharmaceutical company develop anti-inflammatory therapies.
Americas
Amgen antibody patents ‘too broad’, says Fed Circuit
16 February 2021   The US Court of Appeals for the Federal Circuit has invalidated two Amgen antibody patents, finding that their functional claims were too broad.

More on this story

Americas
Haynes Boone hires top biotech patent lawyer
19 July 2022   New partner boosts firm’s biotech practice | Move forms part of life sciences expansion | Role based at Washington, DC office.
Big Pharma
Sanofi and C4X in $493m licensing deal
13 April 2021   UK company C4X Discovery has agreed an exclusive licensing deal with Sanofi worth a potential €414 million, which will see the French pharmaceutical company develop anti-inflammatory therapies.
Americas
Amgen antibody patents ‘too broad’, says Fed Circuit
16 February 2021   The US Court of Appeals for the Federal Circuit has invalidated two Amgen antibody patents, finding that their functional claims were too broad.

More features

Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’
Kilpatrick adds ‘seasoned litigator’ as trademark partner
Startup challenges rival over brain monitoring tech at ITC
UKIPO rejects Boehringer’s SPC for horse inhaler
Bayer, Orion take on Indian generic over $117bn drug
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Bankruptcy judge approves $305m sale of genetics testing company